Monica Kraft is a Respiratory physician affiliated with Icahn School of Medicine at Mount Sinai. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-5656Provider last certified this registry record 14 Sept 2022.
Clinical trials
- Quantifying the Burden of Type 2 (T2) Inflammation in Asthma
Sponsor: Icahn School of Medicine at Mount Sinai
- AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)
Sponsor: Chiesi Farmaceutici S.p.A.
- Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Sponsor: Milton S. Hershey Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202511 payments$37,146openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202519 payments$19,167openpaymentsdata.cms.gov ↗
- Chiesi USA, Inc.Program year20253 payments$12,540openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
73.7%beta2-Adrenergic Agonist30.5%Albuterol Sulfate Hfa100%Part D≥11 patientsCorticosteroid24.6%Flovent Hfa100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
16.9%Corticosteroid16.9%Prednisone100%Part D≥16 patientsDermatology
9.3%Interleukin-4 Receptor alpha Antagonist9.3%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- All of Us Research Program New York Consortium
Icahn School of Medicine at Mount Sinai
FY2026$2,390,000OT2OD037643 - All of Us Research Program New York Consortium
Icahn School of Medicine at Mount Sinai
FY2025$500,000OT2OD037643
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”